Dr. Lu, Qiying joined ImmuneOnco as Chief Medical Officer (CMO) and Senior Vice President (SVP)

On March 21, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") declared the appointment of Dr. Lu, Qiying as Chief Medical Officer (CMO) and Senior Vice President (SVP). Dr. Lu, Qiying, M.D.......

2022-03-20

Dr. Xiong, Zikai joined ImmuneOnco as Senior Vice President（SVP）

On March 15, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced the appointment of Dr. Xiong Zikai as the senior vice president (SVP) to be fully responsible for the company's BD affairs. ......

2022-03-15

ImmueOco: The Invention patent for IMM0306 was authorized by Japan Patent Office

On March 9, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") declared that IMM0306, a bispecific fusion protein targeting CD47 and CD20 was authorized by the Japan Patent Office (Japanese Patent Applicatio......

2022-03-10

NMPA approved phase Ib/II clinical trial application of ImmuneOnco for IMM01 combined with PD-1 antibody in the treatment of relapsed and refractory malignant tumors

On February 22, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced that National Medical Products Administration (NMPA) approved Phase Ib/II clinical trial application of the first domestic SIRPα-F......

2022-02-22

IMM2902 of ImmuneOnco Completed the First Patient Dosing

February 15, 2022, Shanghai, China. ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco", the company) announced that the first bispecific antibody-receptor recombinant protein (project number: IMM2902) targeting hum......

2022-02-15